← All peptidesGrowth Hormone Axis
Tesamorelin
Tesamorelin acetate (Egrifta)
GHRH analog. FDA-approved for HIV-associated lipodystrophy. Visceral fat reduction, IGF-1 elevation.
Typical dose
1–2 mg
Frequency
Once daily, evening preferred
Half-life
0.5 h
Route
subcutaneous
Typical vial sizes
2 mg5 mg10 mg
Sample reconstitution
2 mg vial · 2 mL bac water · 1.5 mg dose
- Draw volume
- 1.500 mL
- Insulin units
- 150 units
- Concentration
- 1.00 mg/mL
- Doses per vial
- 1.3
Research notes
Most clinically validated GHRH. Monitor IGF-1 quarterly.
Research use only.
Information on this page is a reference log compiled from public sources and is not medical advice. Consult a licensed physician before making any decisions about your health.